<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18923" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Restrictive Cardiomyopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Brown</surname>
            <given-names>Kristen N.</given-names>
          </name>
          <aff>Augusta University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pendela</surname>
            <given-names>Venkata Satish</given-names>
          </name>
          <aff>Rochester General Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ahmed</surname>
            <given-names>Intisar</given-names>
          </name>
          <aff>Aga Khan University Pakistan</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Diaz</surname>
            <given-names>Rene R.</given-names>
          </name>
          <aff>Clinica Shaio</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kristen Brown declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Venkata Satish Pendela declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Intisar Ahmed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rene Diaz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18923.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Restrictive cardiomyopathy (RCM) is characterized by diastolic dysfunction of a non-dilated ventricle. Multiple types of restrictive cardiomyopathies exist and vary in their pathogenesis, clinical presentation, diagnostic evaluation, treatment, and prognosis. Three of the leading causes of RCM are cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis. This activity reviews restrictive cardiomyopathy with particular emphasis on these three major etiologies and outlines the role of team-based interprofessional care for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Define restrictive cardiomyopathy.</p></list-item><list-item><p>Review the types of restrictive cardiomyopathies and their causes.</p></list-item><list-item><p>Review the management strategies for restrictive cardiomyopathies.</p></list-item><list-item><p>Describe how enhanced coordination of the interprofessional team can lead to more rapid detection of restrictive cardiomyopathy and subsequently allow for more prompt treatment when indicated.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18923&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18923">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18923.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Restrictive cardiomyopathy (RCM) is distinguished by&#x000a0;diastolic dysfunction in a non-dilated ventricle. Multiple types of restrictive cardiomyopathies vary according to pathogenesis, clinical presentation, diagnostic evaluation, treatment, and prognosis. Three of the leading causes of RCM include cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis.<xref ref-type="bibr" rid="article-18923.r1">[1]</xref>&#x000a0;In this article, a comprehensive review of RCM will be presented, including a particular emphasis on the three major etiologies of RCM.</p>
      </sec>
      <sec id="article-18923.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There are several causes of restrictive&#x000a0;cardiomyopathy, including infiltrative diseases, storage diseases, and&#x000a0;a variety of systemic diseases. Infiltrative diseases are pathologies that lead to a build-up of a substance in the myocardium. These diseases include amyloidosis (AL, ATTRm, ATTRwt, ApoA-I), sarcoidosis, hereditary&#x000a0;hemochromatosis,&#x000a0;as well as primary hyperoxaluria.<xref ref-type="bibr" rid="article-18923.r1">[1]</xref> Amyloidosis is the most common infiltrative disease. Storage diseases are rare congenital abnormalities in metabolism. Storage diseases include&#x000a0;Anderson-Fabry disease, Gaucher disease, glycogen storage, mucopolysaccharidosis type II (Hurler cardiomyopathy), Niemann-Pick, Danon disease,&#x000a0;and Friedrich ataxia. Several different systemic diseases can also lead to restrictive cardiomyopathy. Some of these pathologies include diabetes, scleroderma, myofibrillar myopathies, pseudoxanthoma elasticum, Werner&#x000a0;syndrome, sarcomeric protein disorders, carcinoid cardiomyopathy, idiopathic fibrosis, hypereosinophilic fibrosis, chronic eosinophilic leukemia fibrosis, endocardial fibroelastosis, and metastatic malignancies. Other causes of restrictive cardiomyopathy include idiopathic causes, including radiation therapy and various pharmaceuticals.<xref ref-type="bibr" rid="article-18923.r2">[2]</xref>&#x000a0;Some drugs known for causing restrictive cardiomyopathy include&#x000a0;anthracycline, busulfan, ergotamines, methysergide, mercurial agents, and serotonin-containing agents.<xref ref-type="bibr" rid="article-18923.r3">[3]</xref><xref ref-type="bibr" rid="article-18923.r4">[4]</xref></p>
      </sec>
      <sec id="article-18923.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>RCM is a fairly rare disease, but it&#x000a0;does account&#x000a0;for approximately 5% of all cases of cardiomyopathy. The three major cardiomyopathies&#x000a0;are dilated, hypertrophic, and restrictive.&#x000a0;RCM is the least common form.&#x000a0;Most causes of RCM are acquired. Its&#x000a0;prevalence varies depending on regionality, ethnicity, age, and gender.<xref ref-type="bibr" rid="article-18923.r5">[5]</xref>&#x000a0;Below are some examples of specific statistics for individual etiologies:</p>
        <list list-type="bullet">
          <list-item>
            <p>Amyloidosis:&#x000a0;The most common cause of RCM in the United States.&#x000a0;It affects men and women equally. AL amyloidosis most common cause of RCM. Several different types of amyloidosis.&#x000a0;The wild-type transthyretin amyloidosis is most often found in the elderly population. The V1221 mutant transthyretin has a higher rate of symptomatic heart failure.<xref ref-type="bibr" rid="article-18923.r6">[6]</xref><xref ref-type="bibr" rid="article-18923.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sarcoidosis:&#x000a0;More common in women than men. The highest prevalence is among black women. The highest incidence worldwide is in Japan.<xref ref-type="bibr" rid="article-18923.r1">[1]</xref><xref ref-type="bibr" rid="article-18923.r7">[7]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hemochromatosis:&#x000a0;Affects men and women equally. The prevalence is 1 per 200 individuals. Men are more likely to have cirrhosis associated with hemochromatosis.&#x000a0;The predominant gene mutation HFE C282Y. It is inherited in an autosomal recessive pattern. Another common mutation&#x000a0;seen in hemochromatosis is the H63D.<xref ref-type="bibr" rid="article-18923.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Loffler endocarditis:&#x000a0;Common in tropical climates and sub-Saharan Africa. Up to twenty percent of heart failure in this region is thought to be secondary to endomyocardial fibrosis.<xref ref-type="bibr" rid="article-18923.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>There are several other causes of restrictive cardiomyopathy, each of which has its unique epidemiology. They all vary by region, gender variance, incidence, prevalence, and mutation affected. These conditions are not mentioned in detail&#x000a0;here as they are much rarer than the above. If any of the above does not fit the patient's diagnosis, then the recommendation is to consult a specialist if one is not already involved.</p>
      </sec>
      <sec id="article-18923.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Most restrictive cardiomyopathies are due to infiltration of abnormal substances between myocytes, storage of abnormal metabolic products within myocytes, or fibrotic injury.</p>
        <p>
<bold>Infiltrative (Between Myocytes)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Amyloidosis</p>
          </list-item>
          <list-item>
            <p>Primary (light chain amyloid)</p>
          </list-item>
          <list-item>
            <p>Familial (abnormal transthyretin)</p>
          </list-item>
          <list-item>
            <p>Senile (normal transthyretin or atrial peptides)</p>
          </list-item>
          <list-item>
            <p>Inherited metabolic defects</p>
          </list-item>
        </list>
        <p>
<bold>Storage (Within Myocytes)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hemochromatosis (iron)</p>
          </list-item>
          <list-item>
            <p>Inherited metabolic defects</p>
          </list-item>
          <list-item>
            <p>Fabry disease</p>
          </list-item>
          <list-item>
            <p>Glycogen storage disease (II, III)</p>
          </list-item>
        </list>
        <p>
<bold>Fibrotic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Radiation</p>
          </list-item>
          <list-item>
            <p>Scleroderma</p>
          </list-item>
        </list>
        <p>
<bold>Endomyocardial</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Possibly related fibrotic diseases</p>
          </list-item>
          <list-item>
            <p>Tropical endomyocardial fibrosis</p>
          </list-item>
          <list-item>
            <p>Hypereosinophilic syndrome (L&#x000f6;ffler endocarditis)</p>
          </list-item>
          <list-item>
            <p>Carcinoid syndrome</p>
          </list-item>
          <list-item>
            <p>Radiation</p>
          </list-item>
          <list-item>
            <p>Drugs: e.g., serotonin, ergotamine</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18923.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The histology of restrictive cardiomyopathies varies depending on etiology. It is specifically useful with infiltrative cardiomyopathies and some of the storage diseases.&#x000a0;A list of common histology associations are listed below:<xref ref-type="bibr" rid="article-18923.r10">[10]</xref><xref ref-type="bibr" rid="article-18923.r11">[11]</xref><xref ref-type="bibr" rid="article-18923.r12">[12]</xref><xref ref-type="bibr" rid="article-18923.r13">[13]</xref><xref ref-type="bibr" rid="article-18923.r14">[14]</xref><xref ref-type="bibr" rid="article-18923.r15">[15]</xref><xref ref-type="bibr" rid="article-18923.r16">[16]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Amyloidosis: positive&#x000a0;congo red stain&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Sarcoidosis: granulomatosis reaction</p>
          </list-item>
          <list-item>
            <p>Primary hyperoxaluria: oxalate deposition</p>
          </list-item>
          <list-item>
            <p>Niemann-Pick: foam cells</p>
          </list-item>
          <list-item>
            <p>Mucopolysaccharidosis type II: glycosaminoglycans</p>
          </list-item>
          <list-item>
            <p>Glycogen storage dicarboxylic acids</p>
          </list-item>
          <list-item>
            <p>Hereditary hemochromatosis (iron)</p>
          </list-item>
          <list-item>
            <p>Gaucher: Gaucher cells (lipid-laden macrophages)</p>
          </list-item>
          <list-item>
            <p>Fabry: ceramide trihexoside</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18923.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with RCM primarily present with advanced disease and obvious signs of cardiopulmonary compromise, but in some&#x000a0;circumstances, the diagnosis is incidental. It is important to suspect RCM in any patient with a normal or close to normal systolic function and evidence of diastolic dysfunction with a restrictive filling pattern on echocardiogram. For those that present symptomatically, there is a wide range of presentations. Some may&#x000a0;present&#x000a0;in&#x000a0;full-blown&#x000a0;heart&#x000a0;failure&#x000a0;(jugular venous distension, ascites, lower extremity edema, and less&#x000a0;commonly pulmonary edema).&#x000a0;Some may&#x000a0;complain of poor exercise tolerance or&#x000a0;be newly diagnosed&#x000a0;with an arrhythmia such as atrial fibrillation. In the less fortunate cases,&#x000a0;some present as sudden cardiac arrest (SCD). Other less common presentations include ischemia, thrombus, and misdiagnosed as hypertrophic cardiomyopathy with left ventricular outflow obstruction. When performing the evaluation and physical in a patient suspected of&#x000a0;RCM,&#x000a0;it is essential to look for extracardiac manifestations such as carpal tunnel, which may be present in amyloidosis or bilateral hilar infiltrates seen in sarcoidosis.<xref ref-type="bibr" rid="article-18923.r17">[17]</xref>&#x000a0;Hemochromatosis may present with the classic bronze skin, cirrhosis, arthralgias, and endocrinopathies such as diabetes mellitus.<xref ref-type="bibr" rid="article-18923.r18">[18]</xref></p>
        <p>The cardiac impulse is less displaced than in dilated cardiomyopathy and less dynamic than in hypertrophic cardiomyopathy. A fourth heart sound is more common than a third heart sound in sinus rhythm, but atrial fibrillation is common. Jugular venous pressures often show rapid Y descents and may increase during inspiration (positive Kussmaul&#x02019;s sign).</p>
      </sec>
      <sec id="article-18923.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Electrocardiogram (ECG) is one of the first tools used when a cardiac diagnosis&#x000a0;is suspected. For example, a low-to-normal voltage in&#x000a0;the&#x000a0;QRS complex despite thickened cardiac muscle in the absence of valvular or hypertensive disease may lead one to suspect amyloidosis. However, the absence of low voltage does not exclude the diagnosis.<xref ref-type="bibr" rid="article-18923.r19">[19]</xref></p>
        <p>The echocardiogram is the primary radiographic diagnostic test for identifying patients with RCM. It may help aid in differentiating RCM from some of its common imitators, such as constrictive pericarditis. The echocardiogram may also provide information to suggest a specific diagnosis. Cardiac magnetic resonance (CMR) imaging can also aid in the diagnosis.&#x000a0;Endomyocardial&#x000a0;biopsy (EMB) may help establish the diagnosis&#x000a0;in some cases&#x000a0;if the primary workup&#x000a0;has not been able to&#x000a0;do so.&#x000a0;Cardiac MRI can be useful to gain ancillary evidence to support a diagnosis of RCM, specifically in amyloidosis, where a gadolinium enhancement pattern is highly suggestive of amyloid.&#x000a0;Nuclear imaging can also be used to aid in diagnosis as it also demonstrates an affinity for amyloid.<xref ref-type="bibr" rid="article-18923.r3">[3]</xref>&#x000a0;Biomarkers such as troponin T, B-type natriuretic peptide (BNP), and pro-BNP are also useful diagnostic and prognostic factors.&#x000a0;</p>
        <p>For a definitive diagnosis, a biopsy or aspirate is required. EMB is the gold standard for the diagnosis of cardiac amyloidosis.<xref ref-type="bibr" rid="article-18923.r19">[19]</xref>&#x000a0;Fat pad aspiration is positive in about 50% of cases.&#x000a0;Mass spectrometry, the gold standard for typing the tissue, is done following biopsy to evaluate further the disease process. Mutation analysis can diagnose hereditary hemochromatosis, especially due to the strong association with the HFE C282Y and H63D.&#x000a0;</p>
      </sec>
      <sec id="article-18923.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment for RCM includes treating the underlying cause and heart failure symptoms that may arise secondary to the disease.&#x000a0;Currently,&#x000a0;there is no cure for RCM, but&#x000a0;there&#x000a0;are&#x000a0;some&#x000a0;treatments available to&#x000a0;alleviate&#x000a0;the&#x000a0;symptoms&#x000a0;of the disease. For heart failure symptoms, diuretics are the mainstay of&#x000a0;treatment to reduce volume overload but must&#x000a0;be monitored&#x000a0;closely to&#x000a0;prevent excessive diuresis as&#x000a0;patients&#x000a0;with RCM rely on high filling pressures to maintain cardiac output.&#x000a0;The use of&#x000a0;beta-blockers or calcium channel blockers&#x000a0;is sometimes introduced&#x000a0;to increase the filling&#x000a0;time.<xref ref-type="bibr" rid="article-18923.r4">[4]</xref>&#x000a0;They may also be&#x000a0;beneficial&#x000a0;in treating&#x000a0;dysrhythmias, which are&#x000a0;common in this patient population. Angiotensin-receptor blockers may also&#x000a0;be used,&#x000a0;especially if concurrent systolic heart&#x000a0;failure develops.</p>
        <p>For sarcoidosis, antiarrhythmics are a common therapy choice due to the high incidence of conduction disease. Immunosuppressive agents such as corticosteroids and steroid-sparing agents are also sometimes used to treat sarcoidosis. For hemochromatosis, the treatment of choice is therapeutic phlebotomy. Advanced heart&#x000a0;failure treatment, such as cardiac transplant or left ventricular assist devices, may be appropriate for some patients.<xref ref-type="bibr" rid="article-18923.r3">[3]</xref>&#x000a0;Ultimately, the&#x000a0;choice of a specific therapy depends on the clinical condition, the risk of dangerous events, and the ability of the patient to tolerate the therapy.</p>
      </sec>
      <sec id="article-18923.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>There are several differential diagnoses to keep in mind when evaluating a patient for restrictive cardiomyopathy (RCM).<xref ref-type="bibr" rid="article-18923.r3">[3]</xref>&#x000a0;A few of the common ones are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Constrictive pericarditis</p>
          </list-item>
          <list-item>
            <p>Acute or chronic heart failure</p>
          </list-item>
          <list-item>
            <p>Hypertensive heart disease</p>
          </list-item>
          <list-item>
            <p>Hypertrophic cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Acute or chronic pericarditis</p>
          </list-item>
        </list>
        <p>Constrictive pericarditis (CP) is the most commonly mistaken for restrictive cardiomyopathy (RCM) out of the list above. That is why it is essential to explore the similarities and differences in more detail. The two diseases present almost identically, except for a few key signs and symptoms. Juglar venous distension, Kussmaul sign, and diastolic sounds are both seen in RCM and CP. However, there are some subtle differences. For example, S3 and elevated BNP are far more common in RCM. Whereas a pericardial knock, pericardial calcifications on chest x-ray, pericardial thickening on imaging, and BNP levels less than 100 are more likely seen in constrictive pericarditis. Furthermore, one clear difference between the two diseases is the presence of&#x000a0;ventricular interdependence. Ventricular dependence seen only in CP is described as an increased filling&#x000a0;of one of the ventricles only, with a reciprocal decreased filling of the other ventricle.<xref ref-type="bibr" rid="article-18923.r20">[20]</xref></p>
      </sec>
      <sec id="article-18923.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Similar to the other cardiomyopathies, restrictive cardiomyopathy (RCM) has a very poor prognosis, having the worst prognosis as compared to all other cardiomyopathies. Statistical studies&#x000a0;report only a 2 to 5 year survival rate.<xref ref-type="bibr" rid="article-18923.r3">[3]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-18923.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of RCM may include&#x000a0;the following:<xref ref-type="bibr" rid="article-18923.r21">[21]</xref><xref ref-type="bibr" rid="article-18923.r3">[3]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Thromboembolism</p>
          </list-item>
          <list-item>
            <p>Dysrhythmias</p>
          </list-item>
          <list-item>
            <p>Heart failure</p>
          </list-item>
          <list-item>
            <p>Cardiac cirrhosis</p>
          </list-item>
          <list-item>
            <p>Extra-cardiac manifestations depending on etiology</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18923.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Restrictive cardiomyopathy is such a complex diagnosis it is best to consult or refer the patient to&#x000a0;a cardiologist. Other consults that may merit consideration will depend on the extent of the disease; these consults include palliative care, hospice, and possibly advanced heart failure specialist.</p>
      </sec>
      <sec id="article-18923.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Proper and thorough patient education is essential with a diagnosis of restrictive cardiomyopathy. Ultimately, most forms of this disease are fatal. The patient must understand this fact, as modern medicine has no cure for RCM. The key steps which should be made early in the disease course, including educating the patient and their loved ones regarding the disease course and prognosis.&#x000a0;Then a heart transplant evaluation should be obtained, followed by a heart failure consult, possible palliative care consult, and possible hospice consult depending on the patient's wishes.<xref ref-type="bibr" rid="article-18923.r22">[22]</xref></p>
      </sec>
      <sec id="article-18923.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Early diagnosis followed by immediate&#x000a0;initiation of an interprofessional approach, including a heart failure nurse, heart failure specialist, palliative care, specialized cardiac pharmacist, the patient's primary care provider, and multiple other specialists, is the key to enhancing outcomes.<xref ref-type="bibr" rid="article-18923.r23">[23]</xref>&#x000a0;Cardiology nurses and pharmacists educate patients about compliance, medication side effects and provide updates to the team. It would be optimal to discuss all aspects of the disease with the patient as well as include them in the team discussions. Studies have shown patients live longer, have fewer hospital admissions, and are overall more satisfied with their healthcare with this approach.</p>
      </sec>
      <sec id="article-18923.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18923&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18923">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/restrictive-cardiomyopathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18923">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18923/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18923">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18923.s17">
        <title>References</title>
        <ref id="article-18923.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Costabel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Wessendorf</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Bonella</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>[Epidemiology and Clinical Presentation of Sarcoidosis].</article-title>
            <source>Klin Monbl Augenheilkd</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>234</volume>
            <issue>6</issue>
            <fpage>790</fpage>
            <page-range>790-795</page-range>
            <pub-id pub-id-type="pmid">27454307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armanious</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mohammadi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Khodor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oliver</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Johnstone</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Fradley</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular effects of radiation therapy.</article-title>
            <source>Curr Probl Cancer</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>433</fpage>
            <page-range>433-442</page-range>
            <pub-id pub-id-type="pmid">30006103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muchtar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Blauwet</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.</article-title>
            <source>Circ Res</source>
            <year>2017</year>
            <month>Sep</month>
            <day>15</day>
            <volume>121</volume>
            <issue>7</issue>
            <fpage>819</fpage>
            <page-range>819-837</page-range>
            <pub-id pub-id-type="pmid">28912185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rammos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meladinis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vovas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Patsouras</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Restrictive Cardiomyopathies: The Importance of Noninvasive Cardiac Imaging Modalities in Diagnosis and Treatment-A Systematic Review.</article-title>
            <source>Radiol Res Pract</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>2874902</fpage>
            <pub-id pub-id-type="pmid">29270320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ortolani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Traini</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Caporale</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferlito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Branzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Magnani</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>[Restrictive cardiomyopathies].</article-title>
            <source>Cardiologia</source>
            <year>1993</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>12 Suppl 1</issue>
            <fpage>283</fpage>
            <page-range>283-8</page-range>
            <pub-id pub-id-type="pmid">8020028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kyriakou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mouselimis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tsarouchas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rigopoulos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bakogiannis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Noutsias</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vassilikos</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers.</article-title>
            <source>BMC Cardiovasc Disord</source>
            <year>2018</year>
            <month>Dec</month>
            <day>04</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>221</fpage>
            <pub-id pub-id-type="pmid">30509186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nunes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Freynet</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Naggara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Soussan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weinman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Diebold</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brillet</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Valeyre</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cardiac sarcoidosis.</article-title>
            <source>Semin Respir Crit Care Med</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>428</fpage>
            <page-range>428-41</page-range>
            <pub-id pub-id-type="pmid">20665393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lor&#x000e9;al</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cavey</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Robin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kenawi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guggenbuhl</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brissot</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Iron as a Therapeutic Target in <italic>HFE</italic>-Related Hemochromatosis: Usual and Novel Aspects.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2018</year>
            <month>Nov</month>
            <day>26</day>
            <volume>11</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">30486249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bhatti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bandlamudi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopez-Mattei</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <chapter-title>Endomyocardial Fibrosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">30020665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ry&#x00161;av&#x000e1;</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>AL amyloidosis: advances in diagnostics and treatment.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2019</year>
            <month>Sep</month>
            <day>01</day>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>1460</fpage>
            <page-range>1460-1466</page-range>
            <pub-id pub-id-type="pmid">30299492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doubkov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Panovsk&#x000fd;</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[How to diagnose cardiac sarcoidosis?].</article-title>
            <source>Vnitr Lek</source>
            <year>2018</year>
            <season>Fall</season>
            <volume>64</volume>
            <issue>7-8</issue>
            <fpage>729</fpage>
            <page-range>729-733</page-range>
            <pub-id pub-id-type="pmid">30441980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baldo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tavares</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Poletto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>FQ</given-names>
              </name>
              <name>
                <surname>Matte</surname>
                <given-names>UD</given-names>
              </name>
              <name>
                <surname>Giugliani</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity.</article-title>
            <source>Cardiovasc Pathol</source>
            <year>2017</year>
            <season>Mar-Apr</season>
            <volume>27</volume>
            <fpage>45</fpage>
            <page-range>45-50</page-range>
            <pub-id pub-id-type="pmid">28104572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grafft</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Semret</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Orloff</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Renal involvement in Neimann-Pick Disease.</article-title>
            <source>NDT Plus</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>2</volume>
            <issue>6</issue>
            <fpage>448</fpage>
            <page-range>448-51</page-range>
            <pub-id pub-id-type="pmid">25949377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burrow</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Prada</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Setchell</surname>
                <given-names>KDR</given-names>
              </name>
              <name>
                <surname>Witte</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Grabowski</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings.</article-title>
            <source>Mol Genet Metab</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>114</volume>
            <issue>2</issue>
            <fpage>233</fpage>
            <page-range>233-241</page-range>
            <pub-id pub-id-type="pmid">25219293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sweet</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Mestroni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>MRG</given-names>
              </name>
            </person-group>
            <article-title>Genetic Infiltrative Cardiomyopathies.</article-title>
            <source>Heart Fail Clin</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>215</fpage>
            <page-range>215-224</page-range>
            <pub-id pub-id-type="pmid">29525649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thosani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Younes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>A heart of stone.</article-title>
            <source>Gastroenterology</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>145</volume>
            <issue>1</issue>
            <fpage>e6</fpage>
            <page-range>e6-e7</page-range>
            <pub-id pub-id-type="pmid">23727481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ruberg</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>Early Diagnosis of Cardiac Amyloidosis by Carpal Tunnel Surgery: Is it All in the Wrist?</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>23</day>
            <volume>72</volume>
            <issue>17</issue>
            <fpage>2051</fpage>
            <page-range>2051-2053</page-range>
            <pub-id pub-id-type="pmid">30336829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Porter</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rawla</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Hemochromatosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">28613612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Rapezzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Plant&#x000e9;-Bordeneuve</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Karayal</surname>
                <given-names>ON</given-names>
              </name>
              <name>
                <surname>Mundayat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Suhr</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>Kristen</surname>
                <given-names>AV</given-names>
              </name>
            </person-group>
            <article-title>Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy.</article-title>
            <source>Open Heart</source>
            <year>2016</year>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>e000289</fpage>
            <pub-id pub-id-type="pmid">26870387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Constrictive Pericarditis Versus Restrictive&#x000a0;Cardiomyopathy?</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>May</month>
            <day>03</day>
            <volume>67</volume>
            <issue>17</issue>
            <fpage>2061</fpage>
            <page-range>2061-76</page-range>
            <pub-id pub-id-type="pmid">27126534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okada</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Derakhshan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gowani</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Misra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tandri</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chrispin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Ventricular Arrhythmias in Cardiac Sarcoidosis.</article-title>
            <source>Circulation</source>
            <year>2018</year>
            <month>Sep</month>
            <day>18</day>
            <volume>138</volume>
            <issue>12</issue>
            <fpage>1253</fpage>
            <page-range>1253-1264</page-range>
            <pub-id pub-id-type="pmid">30354431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Senderovich</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>It's Time to Talk: Challenges in Providing Integrated Palliative Care in Advanced Congestive Heart Failure. A Narrative Review.</article-title>
            <source>Curr Cardiol Rev</source>
            <year>2018</year>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <page-range>128-137</page-range>
            <pub-id pub-id-type="pmid">29366424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18923.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morton</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Masters</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cowburn</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Multidisciplinary team approach to heart failure management.</article-title>
            <source>Heart</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>104</volume>
            <issue>16</issue>
            <fpage>1376</fpage>
            <page-range>1376-1382</page-range>
            <pub-id pub-id-type="pmid">29170356</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
